Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug

US-based biopharmaceutical company Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra (resmetirom), a drug candidate for compensated non-alcoholic steatohepatitis (NASH) cirrhosis.